info@seagull-health.com
SeagullHealth
search
Avatrombopag(Doptelet)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Enasidenib(Avatrombopag) Instructions:Uses,Dosage, Side Effects
DOPTELET contains the active ingredient avatrombopag and is available as oral tablets and sprinkle capsules. It functions as a thrombopoietin receptor agonist, stimulating the bone marrow to produce more platelets. This medication is used to treat thrombocytopenia in specific patient populations, including those with chronic liver disease scheduled for a procedure and patients with chronic immune thrombocytopenia who have had an insufficient response to prior therapies. It is not intended to normalize platelet counts.
DOPTELET is indicated for the treatment of thrombocytopenia in three distinct patient groups:
Adult patients with chronic liver disease who are scheduled to undergo a procedure.
Adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Pediatric patients 1 year of age and older with persistent or chronic ITP who have had an insufficient response to a previous treatment.
Dosage is individualized based on indication, patient age, and platelet count.
Chronic Liver Disease (Adults): A 5-day oral regimen starting 10-13 days pre-procedure. Dose is 40 mg (2 tablets) or 60 mg (3 tablets) once daily with food, based on pre-procedure platelet count.
Chronic ITP (Adults & Pediatrics ≥6 years): Initial dose is 20 mg (1 tablet) once daily with food. Dose is titrated based on weekly platelet monitoring to achieve and maintain a count ≥50×10⁹/L, not to exceed 40 mg daily. Complex weekly schedules are used for titration.
Chronic ITP (Pediatrics 1 to <6 years): Initial dose is 10 mg (contents of 1 SPRINKLE capsule) once daily mixed with soft food/liquid. Dose is titrated similarly, not to exceed 20 mg daily.
Dosage adjustments are required with concomitant use of moderate or strong dual CYP2C9 and CYP3A4 inhibitors or inducers.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
